SAR441566

Phase 2Small molecule

Sanofi

SAR441566 is one of 105 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

104

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

PsoriasisActive, not recruiting

Ulcerative ColitisActive, not recruiting

Colitis, UlcerativeRecruiting

Rheumatoid ArthritisPhase 2

Active, not recruiting

PsoriasisPhase 2

Active, not recruiting

Ulcerative ColitisPhase 2

Active, not recruiting

Colitis, UlcerativePhase 2

Recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Preclinical

61 2

Actemra

Enbrel

64 4

Remicade

OOrganon and Co

Preclinical

43 5

SAR441566

Sanofi

Phase 2

1 6

Ilaris

Novartis

Preclinical

3 7

Celexa

AbbVie

Preclinical

1 8

Zelhou

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

7 9

Rituxan

Pfizer

Preclinical

7 10

Cimzia

UCB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Colitis, Ulcerative

NCT06867094

Q2 2029

Phase 2Recruiting

Efficacy and Safety

NCT06637631

Clinical

Trials by Indication[1]

Psoriasis2 trials

A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis

Completed· Sanofi logo

Sanofi·Phase 2·NCT06073119·221 enrolled

A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis

Completed· Sanofi logo

Sanofi·Phase 1·NCT05453942·38 enrolled

Rheumatoid Arthritis1 trial

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

Completed· Sanofi logo

Sanofi·Phase 2·NCT06073093·264 enrolled

Efficacy and Safety1 trial

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

Recruiting· Sanofi logo

Sanofi·Phase 2·NCT06637631·260 enrolled

Randomized1 trial

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

Completed· Sanofi logo

Sanofi·Phase 1·NCT05844735·60 enrolled

Single Ascending Dose1 trial

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

Completed· Sanofi logo

Sanofi·Phase 1·NCT05858788·10 enrolled

1 more indication

Colitis, Ulcerative1 trial

A Phase 2, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of SAR441566 in Adults With Moderate-to-severe Ulcerative Colitis

Recruiting· Sanofi logo

Sanofi·Phase 2·NCT06867094·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for SAR441566. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SAR441566 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SAR441566. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Sanofi

SAR441566

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q2 2029

Trials by Indication[1]

Psoriasis2 trials

Rheumatoid Arthritis1 trial

Efficacy and Safety1 trial

Randomized1 trial

Single Ascending Dose1 trial

Colitis, Ulcerative1 trial

References

Drug Info

Quick Facts

Related News